U.S. stocks edge higher; solid earnings season continues
Samarth Kulkarni, the Chief Executive Officer of CRISPR Therapeutics AG (NASDAQ:CRSP), recently sold a significant portion of the company’s stock. The transaction comes as the company, currently valued at $4.1 billion, shows volatile trading patterns according to InvestingPro data. According to a recent SEC filing, Kulkarni sold 18,360 common shares on February 19, 2025, at a weighted average price of $55.205 per share, totaling approximately $1.01 million. These transactions were conducted under a Rule 10b5-1 trading plan, which was adopted on June 13, 2024. Following this sale, Kulkarni holds 171,613 shares directly and an additional 85,622 shares indirectly through The Kulkarni 2023 GRAT. The stock, which analysts give a consensus "Buy" rating with significant upside potential, is currently trading below InvestingPro’s calculated Fair Value. Get comprehensive insider trading analysis and 10+ additional ProTips with an InvestingPro subscription.
In other recent news, CRISPR Therapeutics has reported several significant developments that may interest investors. Citi analysts have adjusted their price target for the company to $82, maintaining a Buy rating, while noting the expansion of Casgevy treatment centers globally, though only a few patients have been treated so far. Evercore ISI has upgraded CRISPR Therapeutics’ stock from In Line to Outperform, raising the price target to $99, driven by optimism about upcoming catalysts and the company’s strong cash position of $1.9 billion. In contrast, Stifel has reduced its price target to $49, maintaining a Hold rating due to cautious expectations for Casgevy’s market uptake. Meanwhile, TD Cowen has upgraded the stock from Sell to Hold, keeping the price target at $35, citing reduced downside risk.
Analysts are particularly focused on CRISPR Therapeutics’ pipeline, with upcoming data from in vivo programs like CTX320 and CTX310 anticipated in 2025. These programs are expected to play a pivotal role in the company’s future, with Evercore ISI assigning probabilities of success at 10% and 5%, respectively. Additionally, updates on second-generation CAR-T therapy CTX112 and other developments are expected around mid-2025. While some analysts remain cautious, others see potential for significant advancements in the company’s gene-editing capabilities. These recent developments highlight the diverse perspectives among analysts regarding CRISPR Therapeutics’ future trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.